Akums Drugs and Pharmaceuticals reported its Q4FY26 earnings with mixed performance, as the company posted a sharp decline in net profit despite healthy growth in revenue and operating performance.
The pharmaceutical company reported a consolidated net profit of ₹81.3 crore for the fourth quarter, down 45.7% year-on-year compared to ₹149.6 crore in the corresponding quarter last year.
However, revenue from operations rose 9.7% YoY to ₹1,157.8 crore against ₹1,055.5 crore reported in the year-ago period, indicating steady business momentum across key segments.
At the operating level, EBITDA witnessed strong growth of 61.6% YoY to ₹151.7 crore, compared to ₹94 crore in Q4FY25. EBITDA margin improved significantly to 13% from 8.9% in the same quarter last year, reflecting better operational efficiency and margin expansion.
Akums Drugs Q4FY26 Highlights
- Net profit fell 45.7% to ₹81.3 crore vs ₹149.6 crore YoY
- Revenue increased 9.7% to ₹1,157.8 crore vs ₹1,055.5 crore YoY
- EBITDA jumped 61.6% to ₹151.7 crore vs ₹94 crore YoY
- EBITDA margin improved to 13% from 8.9% YoY
Shares of Akums Drugs and Pharmaceuticals will remain in focus as the market reacts to the company’s mixed Q4 earnings performance.